SANTA MONICA, Calif., Jan. 6, 2022 /PRNewswire/ — Edmunds was named today to Built In’s Best Places to Work Awards for the second year in a row. Specifically, Edmunds earned a place on Built In’s Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. (“Ginkgo” or the “Company”) (NYSE: DNA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, Read more…
CINCINNATI, Jan. 6, 2022 /PRNewswire/ — P&G Ventures , the early-stage startup studio within Procter & Gamble (PG) – Get Procter & Gamble Company Report, announced Lady Patch as the winner of the 2022 Innovation Read more…
C5 Acquisition Corporation (the “Company”), a special purpose acquisition company, announced the pricing of its initial public offering (“IPO”) of 25,000,000 units at a price of $10.00 per unit. The units will be listed on Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Walmart Inc. (“Walmart” or the “Company”) (NYSE: WMT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Zillow Group, Inc. (“Zillow” or the “Company”) (NASDAQ: Z; ZG) and certain of its officers. The class action, Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Citrix Systems, Inc. (“Citrix” or the “Company”) (CTXS) – Get Citrix Systems, Inc. Report. Such investors are advised to contact Robert Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (NASDAQ: CABA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. Read more…
NEW YORK, Jan. 6, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Regen BioPharma, Inc. (“Regen” or the “Company”) (OTCMKTS: RGBP). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. Read more…